<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1908">
  <stage>Registered</stage>
  <submitdate>31/03/2008</submitdate>
  <approvaldate>31/03/2008</approvaldate>
  <nctid>NCT00651300</nctid>
  <trial_identification>
    <studytitle>A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery</studytitle>
    <scientifictitle>A Multicentre, Double-Blind, Placebo-Controlled Study of the Recovery Benefits Following Treatment With a Cox-2 Regimen in Patients Undergoing Elective Laparoscopic Intra-Peritoneal Abdominal Surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A3481026</secondaryid>
    <secondaryid>PARA-0505-086</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Parecoxib/Valdecoxib
Treatment: drugs - Placebo

Experimental: Group 1 - 

Placebo Comparator: Group 2 - 


Treatment: drugs: Parecoxib/Valdecoxib
A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3

Treatment: drugs: Placebo
A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total intake of morphine in first 4 hours post-surgery upon waking of patients receiving parecoxib versus control group.</outcome>
      <timepoint>4 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of unplanned hospital admissions on Day 4.</outcome>
      <timepoint>4 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Outcomes Recovery Questionnaire on Days 2, 3, and 4.</outcome>
      <timepoint>4 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Collection of adverse events immediately before surgery, 1 and 6 hours after surgery, and on Days 2, 3, and 4.</outcome>
      <timepoint>4 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of stay on Day 1.</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Satisfaction Questionnaire on Days 1 and 4.</outcome>
      <timepoint>4 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Recovery Score on Days 1, 2, and 3.</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Numerical Rating Scale on Days 1 (hourly for 6 hours), 2, 3, and 4.</outcome>
      <timepoint>4 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Modified Brief Pain Inventory on Days 2, 3, and 4.</outcome>
      <timepoint>4 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Readiness for discharge on Day 1.</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female aged 18 to 65 years weighing at least 50 kg but no more than 110 kg
             undergoing elective intra-peritoneal laparoscopic abdominal surgery

          -  American Society of Anaesthesiologists (ASA) Physical Status I-III</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Significant chronic disease, such as renal, hepatic, cardiovascular, or respiratory,
             which would contraindicate participation in the study or interfere with interpretation
             of study results

          -  Active gastrointestinal disease, chronic or acute renal or hepatic disorder, or known
             coagulation defect</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>91</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Port Macquarie</hospital>
    <hospital>Pfizer Investigational Site - Randwick</hospital>
    <hospital>Pfizer Investigational Site - Westmead</hospital>
    <hospital>Pfizer Investigational Site - Coopers Plain</hospital>
    <hospital>Pfizer Investigational Site - Townsville</hospital>
    <hospital>Pfizer Investigational Site - Heidelberg</hospital>
    <hospital>Pfizer Investigational Site - Prahran</hospital>
    <hospital>Pfizer Investigational Site - Perth</hospital>
    <postcode> - Port Macquarie</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4108 - Coopers Plain</postcode>
    <postcode>4814 - Townsville</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>6847 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate morphine intake in the first 4 hours after abdominal
      surgery. Morphine intake is compared between patients on placebo and patients on
      parecoxib/valdecoxib.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00651300</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>